Cargando…
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371089/ https://www.ncbi.nlm.nih.gov/pubmed/34404775 http://dx.doi.org/10.1038/s41467-021-25167-5 |
_version_ | 1783739567374860288 |
---|---|
author | Skelly, Donal T. Harding, Adam C. Gilbert-Jaramillo, Javier Knight, Michael L. Longet, Stephanie Brown, Anthony Adele, Sandra Adland, Emily Brown, Helen Tipton, Tom Stafford, Lizzie Mentzer, Alexander J. Johnson, Síle A. Amini, Ali Tan, Tiong Kit Schimanski, Lisa Huang, Kuan-Ying A. Rijal, Pramila Frater, John Goulder, Philip Conlon, Christopher P. Jeffery, Katie Dold, Christina Pollard, Andrew J. Sigal, Alex de Oliveira, Tulio Townsend, Alain R. Klenerman, Paul Dunachie, Susanna J. Barnes, Eleanor Carroll, Miles W. James, William S. |
author_facet | Skelly, Donal T. Harding, Adam C. Gilbert-Jaramillo, Javier Knight, Michael L. Longet, Stephanie Brown, Anthony Adele, Sandra Adland, Emily Brown, Helen Tipton, Tom Stafford, Lizzie Mentzer, Alexander J. Johnson, Síle A. Amini, Ali Tan, Tiong Kit Schimanski, Lisa Huang, Kuan-Ying A. Rijal, Pramila Frater, John Goulder, Philip Conlon, Christopher P. Jeffery, Katie Dold, Christina Pollard, Andrew J. Sigal, Alex de Oliveira, Tulio Townsend, Alain R. Klenerman, Paul Dunachie, Susanna J. Barnes, Eleanor Carroll, Miles W. James, William S. |
author_sort | Skelly, Donal T. |
collection | PubMed |
description | The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. |
format | Online Article Text |
id | pubmed-8371089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83710892021-09-02 Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern Skelly, Donal T. Harding, Adam C. Gilbert-Jaramillo, Javier Knight, Michael L. Longet, Stephanie Brown, Anthony Adele, Sandra Adland, Emily Brown, Helen Tipton, Tom Stafford, Lizzie Mentzer, Alexander J. Johnson, Síle A. Amini, Ali Tan, Tiong Kit Schimanski, Lisa Huang, Kuan-Ying A. Rijal, Pramila Frater, John Goulder, Philip Conlon, Christopher P. Jeffery, Katie Dold, Christina Pollard, Andrew J. Sigal, Alex de Oliveira, Tulio Townsend, Alain R. Klenerman, Paul Dunachie, Susanna J. Barnes, Eleanor Carroll, Miles W. James, William S. Nat Commun Article The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. Nature Publishing Group UK 2021-08-17 /pmc/articles/PMC8371089/ /pubmed/34404775 http://dx.doi.org/10.1038/s41467-021-25167-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Skelly, Donal T. Harding, Adam C. Gilbert-Jaramillo, Javier Knight, Michael L. Longet, Stephanie Brown, Anthony Adele, Sandra Adland, Emily Brown, Helen Tipton, Tom Stafford, Lizzie Mentzer, Alexander J. Johnson, Síle A. Amini, Ali Tan, Tiong Kit Schimanski, Lisa Huang, Kuan-Ying A. Rijal, Pramila Frater, John Goulder, Philip Conlon, Christopher P. Jeffery, Katie Dold, Christina Pollard, Andrew J. Sigal, Alex de Oliveira, Tulio Townsend, Alain R. Klenerman, Paul Dunachie, Susanna J. Barnes, Eleanor Carroll, Miles W. James, William S. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title_full | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title_fullStr | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title_full_unstemmed | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title_short | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern |
title_sort | two doses of sars-cov-2 vaccination induce robust immune responses to emerging sars-cov-2 variants of concern |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371089/ https://www.ncbi.nlm.nih.gov/pubmed/34404775 http://dx.doi.org/10.1038/s41467-021-25167-5 |
work_keys_str_mv | AT skellydonalt twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT hardingadamc twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT gilbertjaramillojavier twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT knightmichaell twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT longetstephanie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT brownanthony twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT adelesandra twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT adlandemily twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT brownhelen twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tiptontom twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT staffordlizzie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT mentzeralexanderj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT johnsonsilea twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT aminiali twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT tantiongkit twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT schimanskilisa twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT huangkuanyinga twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT rijalpramila twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT fraterjohn twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT goulderphilip twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT conlonchristopherp twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT jefferykatie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT doldchristina twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT pollardandrewj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT sigalalex twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT deoliveiratulio twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT townsendalainr twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT klenermanpaul twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT dunachiesusannaj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT barneseleanor twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT carrollmilesw twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern AT jameswilliams twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern |